NCT03335540View on ClinicalTrials.gov

An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 7, 2018

Primary Completion Date

March 31, 2021

Study Completion Date

August 25, 2021

Conditions
Advanced Cancer
Interventions
BIOLOGICAL

Nivolumab

Specified dose on specified day

BIOLOGICAL

Relatlimab

Specified dose on specified day

BIOLOGICAL

Cabiralizumab

Specified dose on specified day

BIOLOGICAL

Ipilimumab

Specified dose on specified day

DRUG

IDO1 Inhibitor

Specified dose on specified day

RADIATION

Radiation Therapy

Specified dose on specified day

Trial Locations (4)

15232

Local Institution - 0003, Pittsburgh

21287

Local Institution - 0002, Baltimore

60637

Local Institution - 0001, Chicago

University of Chicago, Chicago

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY